|
发表于 22-3-2007 10:55 AM
|
显示全部楼层
原帖由 jkmss007 于 22-3-2007 09:33 AM 发表
公司:Patimas Computers Berhad /PATIMAS (7042)
译名:霸迪马电脑有限公司 (取材光华日报)
项目:〖本周股势〗
日期:26-3 /1-4-2007 (阳历)
签诗:乾坤卦
原句:走尽天涯,风霜历遍,不如问人三天,渐渐 ...
老板,
今天股市大涨
可惜 Patimas 欲振无力
是否是大江东去不复回
发现 Stemlife 0137 奇股也
交易量少 股价稳健上升
可能是下一个明星股
( 老狐狸 VT 也在动 Stemlife 的主意 )
心脏病的干细胞疗法及周边血干细胞的采集过程
心脏病是继癌症之后, 马来西亚的第二号杀手. 早在2003年, 国家心脏中心 (Institut Jantung Negara) 为一名60岁的病人进行干细胞移植手术. 医疗人员把采集自患者盆骨的骨髓干细胞注入心脏, 治疗末期冠状动脉心脏病, 这使得大马成为世界第三个进行这项手术的国家.
2005年8月份, 新生 (StemLife) 与本地一家私人医院 (HSC医疗中心) 合作, 为一名64岁的心脏衰竭患者进行全东南亚首宗成人干细胞注射疗程, 成果令人鼓舞. 与之前的干细胞采集的方式相比, 这位患者使用的是由周边血干细胞 (Peripheral Blood Stem Cell) 中采集的造血干细胞, 而抽取的过程就像捐血或输血一样.
此过程首先从某处静脉引出血, 例如: 手肘内侧静脉, 通过血液分离机把需要的干细胞分离出来. 一次的抽取量可达大约300 - 250毫升 (通常移植手术只需20毫升左右的干细胞, 剩余的储存在干细胞库, 以备不时之需). 由于骨髓的干细胞含量较高, 所以在进行周边血干细胞抽取前, 医生会为患者进行为时5天的干细胞诱导程序. 医生每天在患者静脉注射一种称为"惠尔血添”(Filgrastim) 的刺激剂, 让骨髓里的造血干细胞释放到血液中去. 在第5天刺激剂注射之后的数小时之后, 患者将进行周边血干细胞的采集程序, 又称血浆析离术 (Apheresis). 最上图中的仪器为血液分离机, 最左边的袋子是抗凝剂 (Anticoagulant Citrate Dextrose). 抗凝剂会随着导管流进体内, 目的是为了不让血液在采集的过程中凝结. 由于抗凝剂的使用会造成低血钙的症状, 所以在使用抗凝剂的同时也必须注入葡萄糖酸钙 (Calcium Gluconate) 以补充流失的钙质. 含有丰富干细胞的静脉血从导管进入分离机内, 经高速离心后分离出需要的周边血干细胞及血浆. 一般过程分离出的血浆量为干细胞的一半, 大约150毫升. 最后, 将分离后的血液, 即无干细胞的血液输送回人体, 再进行体内循环.
采集的过程因人而异, 一般需5到6个小时. 基本上, 人不会有任何不适, 无需做额外的休息或调养. 和骨髓干细胞采集的方法相比之下, 从血液中采集干细胞相对的容易许多, 而且患者也无需承受任何痛楚. 再者, 过程中所有使用的导管都是丢弃式及封闭式的, 完全不用担心感染或重复使用.
在无需进行复杂的‘开膛’手术之下, 采集到的干细胞可透过球囊成形术 (Balloon Angioplasty), 通过一枝导管把球囊置入受损的心肌动脉, 扩张之后, 将干细胞直接注射到受损的心肌部分. 干细胞是人体的主干细胞, 肩负着人体各个器官组织的更新及受伤修复等大任. 所以, 在接受干细胞注射后, 受损的心脏能在短时间内恢复一定水平的功能.
周边血干细胞不像骨髓干细胞般难配对及采集, 也不像胚胎干细胞涉及道德伦理的问题. 相信在未来的日子里, 周边血干细胞会更广泛的被应用在疾病的治疗方面, 造福人群.
19-03-2007: Berjaya Sompo, StemLife introduce StemGuard
By Joyce Goh
Email us your feedback at fd@bizedge.com
Berjaya Sompo Insurance Bhd, formerly known as Berjaya General Insurance Bhd, in collaboration with StemLife Bhd, has launched StemGuard, a first-of-its-kind medical insurance policy created exclusively for StemLife clients.
Berjaya Sompo’s chief executive officer Patrick Loh said StemGuard, which was launched on March 1, was specially designed to cover hospital, surgical and transplant expenses arising from a stem cell transplant that used baby cord blood stem cells stored with StemLife.
“StemGuard’s coverage is provided for up to RM100,000 at an affordable premium. This policy is also designed to extend coverage to the child’s siblings, at no additional cost,” he said in a joint press statement on March 19.
"With StemGuard medical insurance plan, parents can now have peace of mind when storing their baby's cord blood with StemLife, knowing that their children can enjoy the benefits StemGuard has to offer," he added.
Cord blood stem cells are ‘master’ cells that can replace diseased cells in the patient with healthy cells through stem cell transplantation.
StemGuard’s coverage encompasses transplants for over 70 types of illnesses, should a StemLife client be diagnosed with any of the conditions and require a stem cell transplant.
Berjaya Sompo provides both individual and group hospital and surgical insurance policies with a network of 16 branch offices and 2,500 agency force nationwide.
StemLife managing director Sharon Low said StemLife provided essential hematological and therapeutical services in collaboration with specialists and medical institutions, which has resulted in successful treatments of prevalent diseases such as cancer, thalassaemia, heart diseases, chronic wounds and trauma injuries.
"StemLife is committed to bringing innovative and caring health and stem cell services to all its value clients," she said. StemLife is an integrated homegrown cord blood and adult stem cell banking and therapeutics company.
[ 本帖最后由 cct2048 于 22-3-2007 11:18 AM 编辑 ] |
|